Christian Daniel Mireles-Dávalos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christian Daniel Mireles-Dávalos has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Bernardo Alfonso Martinez-Guerra
Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán , Mexico City
3 shared publications - Eduardo López-Gutiérrez
Hospital Regional de Alta Especialidad de Oaxaca, Oaxaca City, Mexico
3 shared publications - Elvira Garza-González
Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, México
3 shared publications - Juan Pablo Mena-Ramírez
Hospital General de Zona No.21 IMSS Tepatitlán de Morelos, Tepatitlán de Morelos, Mexico
3 shared publications - Luis Esaú López-Jácome
Departamento de Biología, Facultad de Química, National Autonomous University of Mexico, Mexico City, Mexico
3 shared publications - Talía Pérez-Vicelis
Hospital Regional Tipo B de Alta Especialidad Bicentenario de la Independencia, León, Mexico
3 shared publications
Latest Publications
- Open Access
- 9 February 2026
- Published by Microbiology Society in Microbial Genomics
- Vol. 12 (2) , 001639
Phylogenomic and phenotypic profiling of carbapenem-resistant Pseudomonas aeruginosa clinical isolates reveals lineage-specific resistance mechanisms and adaptive responses
Carbapenem resistance in Pseudomonas aeruginosa is a growing public health concern. Multiple mechanisms of antimicrobial resistance have been described. While surveillance often focuses on carbapenemase detection, non-carbapenemase mechanisms and their interplay with the genomic background remain underexplored. This study aimed to characterize how genomic background influences carbapenem resistance mechanisms and adaptive responses in carbapenem-resistant P. aeruginosa (CRPA). A total of 136 CRPA clinical isolates collected from 28 healthcare centres across Mexico were analysed through core genome phylogeny, sequence type (ST) assignment, resistome profiling, oprD variant analysis, bacterial growth kinetics under imipenem and meropenem exposure and qRT-PCR-based expression of oprD , mexA , mexC , mexE and mexY genes. Isolates clustered into PAO1 and PA14 phylogroups. ST309 was the most prevalent ST (29/136). Pseudomonas paraeruginosa lineage was also identified within these isolates. Phylogenetic clustering of antibiotic resistance genes was observed across phylogroups. In 36% (49/146) of the isolates, β -lactamases ( bla VIM 16%, bla GES 11% and bla IMP 11%) were identified with carbapenemase activity previously reported. Potentially inactivating oprD variants were observed in 75% (102/136) of isolates, with nonsense and frameshift variants associated with resistance phenotypes. Isolates harbouring carbapenemase-encoding genes (CEGs) exhibited stable lag phases regardless of antibiotic exposure, whereas isolates lacking CEGs showed significantly prolonged lag phases. Overexpression of mexA, mexC and mexY genes was observed in 39% (7/18), 17% (3/18) and 39% (7/18) of isolates, respectively, under antibiotic-free condition, and increased under carbapenem exposure. mexA expression was significantly higher in PAO1 isolates (6/18) under antibiotic-free condition and in PA14 isolates under imipenem exposure (5/18). Carbapenem resistance in P. aeruginosa is shaped by both phylogenetic background and antibiotic-driven stress responses. This study provides an integrated analysis of resistance mechanisms – including gene expression and physiological adaptation – across major phylogenetic lineages in clinical isolates recovered in Mexico, underscoring the importance of considering non-carbapenemase resistance pathways in surveillance and treatment strategies.
- 9 February 2026
- Published by Microbiology Society in Microbial Genomics
- Vol. 12 (2) , 001639
Open AccessPhylogenomic and phenotypic profiling of carbapenem-resistant Pseudomonas aeruginosa clinical isolates reveals lineage-specific resistance mechanisms and adaptive responses
Carbapenem resistance in Pseudomonas aeruginosa is a growing public health concern. Multiple mechanisms of antimicrobial resistance have been described. While surveillance often focuses on carbapenemase detection, non-carbapenemase mechanisms and their interplay with the genomic background remain underexplored. This study aimed to characterize how genomic background influences carbapenem resistance mechanisms and adaptive responses in carbapenem-resistant P. aeruginosa (CRPA). A total of 136 CRPA clinical isolates collected from 28 healthcare centres across Mexico were analysed through core genome phylogeny, sequence type (ST) assignment, resistome profiling, oprD variant analysis, bacterial growth kinetics under imipenem and meropenem exposure and qRT-PCR-based expression of oprD , mexA , mexC , mexE and mexY genes. Isolates clustered into PAO1 and PA14 phylogroups. ST309 was the most prevalent ST (29/136). Pseudomonas paraeruginosa lineage was also identified within these isolates. Phylogenetic clustering of antibiotic resistance genes was observed across phylogroups. In 36% (49/146) of the isolates, β -lactamases ( bla VIM 16%, bla GES 11% and bla IMP 11%) were identified with carbapenemase activity previously reported. Potentially inactivating oprD variants were observed in 75% (102/136) of isolates, with nonsense and frameshift variants associated with resistance phenotypes. Isolates harbouring carbapenemase-encoding genes (CEGs) exhibited stable lag phases regardless of antibiotic exposure, whereas isolates lacking CEGs showed significantly prolonged lag phases. Overexpression of mexA, mexC and mexY genes was observed in 39% (7/18), 17% (3/18) and 39% (7/18) of isolates, respectively, under antibiotic-free condition, and increased under carbapenem exposure. mexA expression was significantly higher in PAO1 isolates (6/18) under antibiotic-free condition and in PA14 isolates under imipenem exposure (5/18). Carbapenem resistance in P. aeruginosa is shaped by both phylogenetic background and antibiotic-driven stress responses. This study provides an integrated analysis of resistance mechanisms – including gene expression and physiological adaptation – across major phylogenetic lineages in clinical isolates recovered in Mexico, underscoring the importance of considering non-carbapenemase resistance pathways in surveillance and treatment strategies.
- Open Access
- 9 November 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (22) , 3417
Evaluation of the BD Phoenix Carbapenemase-Producing Organism Panels for the Detection of Carbapenemase Producers in Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa
The classification of carbapenemases can help guide therapy. The present study evaluated the performance of the CPO detection test, included in the BD Phoenix™ NMIC-501 panel for the detection and classification of carbapenemases on the representative molecularly characterized strains collection from Mexico. Carbapenem non-susceptible isolates collected in Mexico were included. The clinical isolates (n = 484) comprised Klebsiella pneumoniae (n = 154), Escherichia coli (n = 150), and P. aeruginosa (n = 180). BD Phoenix CPO NMIC-504 and NMIC-501 panels were used for the identification of species, antimicrobial susceptibility tests, and detection of CPOs. For the detection of carbapenemase-encoding genes, E. coli and K. pneumoniae were evaluated using PCR assays for blaNDM-1, blaKPC, blaVIM, blaIMP, and blaOXA-48-like. For P. aeruginosa, blaVIM, blaIMP, and blaGES were detected using PCR. Regarding E. coli, the CPO panels had a sensitivity of 70% and specificity of 83.33% for the detection of a class B carbapenemase (blaNDM in the molecular test). Regarding K. pneumoniae, the panels had a sensitivity of 75% and specificity of 100% for the detection of a class A carbapenemase (blaKPC in the molecular test). The Phoenix NMIC-501 panels are reliable for detecting class B carbapenemases in E. coli. The carbapenemase classification in K. pneumoniae for class A carbapenemases has a high specificity and PPV; thus, a positive result is of high value.
- 9 November 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (22) , 3417
Open AccessEvaluation of the BD Phoenix Carbapenemase-Producing Organism Panels for the Detection of Carbapenemase Producers in Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa
The classification of carbapenemases can help guide therapy. The present study evaluated the performance of the CPO detection test, included in the BD Phoenix™ NMIC-501 panel for the detection and classification of carbapenemases on the representative molecularly characterized strains collection from Mexico. Carbapenem non-susceptible isolates collected in Mexico were included. The clinical isolates (n = 484) comprised Klebsiella pneumoniae (n = 154), Escherichia coli (n = 150), and P. aeruginosa (n = 180). BD Phoenix CPO NMIC-504 and NMIC-501 panels were used for the identification of species, antimicrobial susceptibility tests, and detection of CPOs. For the detection of carbapenemase-encoding genes, E. coli and K. pneumoniae were evaluated using PCR assays for blaNDM-1, blaKPC, blaVIM, blaIMP, and blaOXA-48-like. For P. aeruginosa, blaVIM, blaIMP, and blaGES were detected using PCR. Regarding E. coli, the CPO panels had a sensitivity of 70% and specificity of 83.33% for the detection of a class B carbapenemase (blaNDM in the molecular test). Regarding K. pneumoniae, the panels had a sensitivity of 75% and specificity of 100% for the detection of a class A carbapenemase (blaKPC in the molecular test). The Phoenix NMIC-501 panels are reliable for detecting class B carbapenemases in E. coli. The carbapenemase classification in K. pneumoniae for class A carbapenemases has a high specificity and PPV; thus, a positive result is of high value.
- Open Access
Active Surveillance of Antimicrobial Resistance and Carbapenemase-Encoding Genes According to Sites of Care and Age Groups in Mexico: Results from the INVIFAR Network
We analyzed the antimicrobial resistance (AMR) data of 6519 clinical isolates of Escherichia coli (n = 3985), Klebsiella pneumoniae (n = 775), Acinetobacter baumannii (n = 163), Pseudomonas aeruginosa (n = 781), Enterococcus faecium (n = 124), and Staphylococcus aureus (n = 691) from 43 centers in Mexico. AMR assays were performed using commercial microdilution systems (37/43) and the disk diffusion susceptibility method (6/43). The presence of carbapenemase-encoding genes was assessed using PCR. Data from centers regarding site of care, patient age, and clinical specimen were collected. According to the site of care, the highest AMR was observed in E. coli, K. pneumoniae, and P. aeruginosa isolates from ICU patients. In contrast, in A. baumannii, higher AMR was observed in isolates from hospitalized non-ICU patients. According to age group, the highest AMR was observed in the ≥60 years age group for E. coli, E. faecium, and S. aureus, and in the 19–59 years age group for A. baumannii and P. aeruginosa. According to clinical specimen type, a higher AMR was observed in E. coli, K. pneumoniae, and P. aeruginosa isolates from blood specimens. The most frequently detected carbapenemase-encoding gene in E. coli was blaNDM (84%).
Open AccessActive Surveillance of Antimicrobial Resistance and Carbapenemase-Encoding Genes According to Sites of Care and Age Groups in Mexico: Results from the INVIFAR Network
We analyzed the antimicrobial resistance (AMR) data of 6519 clinical isolates of Escherichia coli (n = 3985), Klebsiella pneumoniae (n = 775), Acinetobacter baumannii (n = 163), Pseudomonas aeruginosa (n = 781), Enterococcus faecium (n = 124), and Staphylococcus aureus (n = 691) from 43 centers in Mexico. AMR assays were performed using commercial microdilution systems (37/43) and the disk diffusion susceptibility method (6/43). The presence of carbapenemase-encoding genes was assessed using PCR. Data from centers regarding site of care, patient age, and clinical specimen were collected. According to the site of care, the highest AMR was observed in E. coli, K. pneumoniae, and P. aeruginosa isolates from ICU patients. In contrast, in A. baumannii, higher AMR was observed in isolates from hospitalized non-ICU patients. According to age group, the highest AMR was observed in the ≥60 years age group for E. coli, E. faecium, and S. aureus, and in the 19–59 years age group for A. baumannii and P. aeruginosa. According to clinical specimen type, a higher AMR was observed in E. coli, K. pneumoniae, and P. aeruginosa isolates from blood specimens. The most frequently detected carbapenemase-encoding gene in E. coli was blaNDM (84%).